Clinical trials present a new approach using immunotherapy

After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies could revolutionize the landscape of bladder cancer treatment.

Melanoma treatment: Is a genetically altered herpes virus the answer?

How do cancer vaccines work?

Scientists engineer potent immune cells for 'off-the-shelf' cancer immunotherapy

Opinion Cancer Drug Advancements Give New Hope to Metastatic Patients - The New York Times

New mRNA Pancreatic Cancer Vaccine Trial Starts Next Phase

Lung cancer immunotherapy: progress, pitfalls, and promises, Molecular Cancer

cellular and molecular pharmacology - presentation

CRISPR Clinical Trials: A 2023 Update - Innovative Genomics Institute (IGI)

Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy Trials

Cancers, Free Full-Text

Drug combo marks advance against bladder cancer